Reference Detail

Ref Type

PMID

(34709738)

Authors

Masanas M, Masiá N, Suárez-Cabrera L, Olivan M, Soriano A, Majem B, Devis-Jauregui L, Burgos-Panadero R, Jiménez C, Rodriguez-Sodupe P, Boloix A, Toledano I, Guillén G, Navarro A, Llobet-Navas D, Villanueva A, Sánchez de Toledo J, Roma J, Noguera R, Moreno L, Krauss R, Gallego S, Santamaria A, Segura MF

Title

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Clinical and translational medicine	11	10	2021 Oct	e533	Clin Transl Med

URL

Abstract Text

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
ALK F1174L	neuroblastoma	sensitive	4SC-205 + Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of 4SC-205 and Zykadia (ceritinib) inhibited viability to a greater degree than either therapy alone in neuroblastoma cell lines harboring ALK F1174L (PMID: 34709738).	34709738
NRAS Q61K	neuroblastoma	sensitive	4SC-205 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of 4SC-205 and Koselugo (selumetinib) inhibited viability to a greater degree than either therapy alone in a neuroblastoma cell line harboring NRAS Q61K (PMID: 34709738).	34709738
ALK F1174L	neuroblastoma	sensitive	4SC-205 + Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of 4SC-205 and Lorbrena (lorlatinib) inhibited viability to a greater degree than either therapy alone in neuroblastoma cell lines harboring ALK F1174L (PMID: 34709738).	34709738